3,3′,4,4′,5,5′-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model

Journal of Investigative Dermatology

Volumn 130, Issue 6, 2010, Pages 1668-1679

  Paulitschke, Verena ^a   Schicher, Nikolaus ^a   Szekeres, Thomas ^b   Jäger, Walter ^c   Elbling, Leonilla ^b   Riemer, Angelika B ^a   Scheiner, Otto ^b   Trimurtulu, Golakoti ^d   Venkateswarlu, Somepalli ^d   Mikula, Mario ^a   Swoboda, Alexander ^a   Fiebiger, Edda ^e   Gerner, Christopher ^b   Pehamberger, Hubert ^a   Kunstfeld, Rainer ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d Laila Impex R and D Center Unit i   (India)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',4,4',5,5' HEXAHYDROXYSTILBENE; CYCLIN DEPENDENT KINASE 2; P21 ACTIVATED KINASE; PAXILLIN; PROTEIN KINASE; PROTEIN P53; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; 3,3',4,4',5,5'-HEXAHYDROXYSTILBENE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE; PYROGALLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; METASTASIS; MISMATCH REPAIR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; CELL CYCLE; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FEMALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MELANOMA; MICE; MICE, SCID; PAXILLIN; PYROGALLOL; SKIN NEOPLASMS; STILBENES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952423813     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.376     Document Type: Article

References (45)

1. Brown R, Hirst GL, Gallagher WM et al. (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15:45-52
2. Buermeyer AB, Deschenes SM, Baker SM et al. (1999) Mammalian DNA mismatch repair. Annu Rev Genet 33:533-564
3. Chen J, Sadowski I (2005) Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci USA 102:4813-4818
4. Dadras SS, Lange-Asschenfeldt B, Velasco P et al. (2005) Tumor lymphan-giogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 18:1232-1242
5. 2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 58:767-778
6. Deakin NO, Turner CE (2008) Paxillin comes of age. J Cell Sci 121: 2435-2444
7. Delmas D, Passilly-Degrace P, Jannin B et al. (2002) Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells. Int J Mol Med 10:193-199
8. Duckett DR, Bronstein SM, Taya Y et al. (1999) hMutSalpha-and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci USA 96:12384-12388 (Pubitemid 29513511)
9. Feng Q, Albeck JG, Cerione RA et al. (2002) Regulation of the Cool/Pix proteins: key binding partners of the Cdc42/Rac targets, the p21-activated kinases. J Biol Chem 277:5644-5650
10. Filipenko NR, Attwell S, Roskelley C et al. (2005) Integrin-linked kinase activity regulates Rac-and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX. Oncogene 24:5837-5849
11. Harper JW, Adami GR, Wei N et al. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816
12. 2 cell cycle checkpoint. Cancer Res 55:3721-3725
13. Heckman CA, Demuth JG, Deters D et al. (2009) Relationship of p21-activated kinase (PAK) and filopodia to persistence and oncogenic transformation. J Cell Physiol 220:576-585
14. Helma C, Uhl M (2000) A public domain image-analysis program for the single-cell gel-electrophoresis (comet) assay. Mutat Res 466:9-15
15. Hoeller C, Thallinger C, Pratscher B et al. (2005) The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol 124:1293-1299
16. Horvath Z, Murias M, Saiko P et al. (2006) Cytotoxic and biochemical effects of 3,3,4,4,5,5-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp Hematol 34:1377-1384
17. Houtgraaf JH, Versmissen J, van der Giessen WJ (2006) A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med 7:165-172
18. 2. Cancer Res 59:2596-2601
19. Hsieh TC, Wang Z, Hamby CV et al. (2005) Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 334:223-230
20. Huang C, Ma WY, Goranson A et al. (1999) Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20:237-242
21. Kunstfeld R, Wickenhauser G, Michaelis U et al. (2003) Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 120:476-482
22. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15-16
23. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
24. Loewe R, Valero T, Kremling S et al. (2006) Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res 66:11888-11896
25. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51-65
26. Mueller BM, Romerdahl CA, Trent JM et al. (1991) Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res 51:2193-2198
27. Murias M, Handler N, Erker T et al. (2004) Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 12:5571-5578
28. Murias M, Jager W, Handler N et al. (2005) Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 69:903-912
29. Murias M, Luczak MW, Niepsuj A et al. (2008) Cytotoxic activity of 3,3,4,4,5,5-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol In Vitro 22:1361-1370
30. Niles RM, Cook CP, Meadows GG et al. (2006) Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 136:2542-2546
31. Paulitschke V, Kunstfeld R, Mohr T et al. (2009) Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res 8:2501-2510
32. Qin Q, Baudry M, Liao G et al. (2009) A novel function for p53: regulation of growth cone motility through interaction with Rho kinase. J Neurosci 29:5183-5192
33. 2 phase transition. Biochem Biophys Res Commun 250:53-58
34. Sahai E, Marshall CJ (2003) Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteo-lysis. Nat Cell Biol 5:711-719
35. Saiko P, Horvath Z, Murias M et al. (2006) Antitumor effects of 3,3,4,4,5,5-hexahydroxystilbene in HL-60 human promyelocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids 25:1013-1017
36. Scherer SJ, Maier SM, Seifert M et al. (2000) p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J Biol Chem 275:37469-37473
37. Shieh SY, Ikeda M, Taya Y et al. (1997) DNA damage-induced phosphoryla-tion of p53 alleviates inhibition by MDM2. Cell 91:325-334
38. Smalley KS, Brafford P, Haass NK et al. (2005) Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166:1541-1554
39. Svitkina TM, Bulanova EA, Chaga OY et al. (2003) Mechanism of filopodia initiation by reorganization of a dendritic network. J Cell Biol 160:409-421
40. Tice RR, Agurell E, Anderson D et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221
41. Warnick CT, Dabbas B, Ford CD et al. (2001) Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. J Biol Chem 276: 27363-27370
42. Welch MD, Mullins RD (2002) Cellular control of actin nucleation. Annu Rev Cell Dev Biol 18:247-288
43. Wilson KS (2006) Clinical activity of celecoxib in metastatic malignant melanoma. Cancer Invest 24:740-746
44. Wimmer H, Gundacker NC, Griss J et al. (2009) Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells. Electrophoresis 30:2076-2089
45. Xiong Y, Hannon GJ, Zhang H et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704